# Study of Weekly Cabazitaxel for Advanced Prostate Cancer

> **NCT01518283** · PHASE2 · COMPLETED · sponsor: **Spanish Oncology Genito-Urinary Group** · enrollment: 74 (actual)

## Conditions studied

- Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** Cabazitaxel 10 mg/m2

## Key facts

- **NCT ID:** NCT01518283
- **Lead sponsor:** Spanish Oncology Genito-Urinary Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2016-06
- **Final completion:** 2016-07
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518283, "Study of Weekly Cabazitaxel for Advanced Prostate Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01518283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*